M
Masakazu Toi
Researcher at Kyoto University
Publications - 658
Citations - 28522
Masakazu Toi is an academic researcher from Kyoto University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 69, co-authored 578 publications receiving 23200 citations. Previous affiliations of Masakazu Toi include The Breast Cancer Research Foundation & Tokyo Metropolitan Komagome Hospital.
Papers
More filters
Journal ArticleDOI
In situ adipogenesis in fat tissue augmented by collagen scaffold with gelatin microspheres containing basic fibroblast growth factor.
TL;DR: It is concluded that the repeated administration of collagen scaffold and microspheres containing bFGF is a promising way to achieve adipose tissue regeneration inside inherent fat tissue in a minimally invasive manner.
Journal ArticleDOI
Real-time 3D Photoacoustic Visualization System with a Wide Field of View for Imaging Human Limbs.
Kenichi Nagae,Yasufumi Asao,Yoshiaki Sudo,Naoyuki Murayama,Yuusuke Tanaka,Katsumi Ohira,Yoshihiro Ishida,Atsushi Otsuka,Yoshiaki Matsumoto,Susumu Saito,Moritoshi Furu,Koichi Murata,Hiroyuki Sekiguchi,Masako Kataoka,Aya Yoshikawa,Tomoko Ishii,Kaori Togashi,Tsuyoshi Shiina,Kenji Kabashima,Masakazu Toi,Takayuki Yagi +20 more
TL;DR: A PAI prototype system equipped with an HDA suitable for imaging limbs could be developed that could be scanned over a wide range while in a more comfortable position, and high-quality still images and motion pictures could be obtained.
Journal ArticleDOI
Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: prognostic implications.
Masakazu Toi,Massimo Gion,Elia Biganzoli,Ruggero Dittadi,Patrizia Boracchi,Rosalba Miceli,S. Meli,Kazushige Mori,Takeshi Tominaga,Giampietro Gasparini +9 more
TL;DR: This is the first study showing in vivo that two different angiogenic peptides concur in the progression of human breast cancer, suggesting a possible potentiation of the capability of predicting the likelihood of recurrence by the co-determination of TP and VEGF.
Journal ArticleDOI
Expansion of human γδ T cells for adoptive immunotherapy using a bisphosphonate prodrug
Yoshimasa Tanaka,Yoshimasa Tanaka,Kaoru Murata-Hirai,Masashi Iwasaki,Kenji Matsumoto,Kosuke Hayashi,Asuka Kumagai,Mohanad H. Nada,Hong Wang,Hirohito Kobayashi,Hiroshi Kamitakahara,Haruki Okamura,Tomoharu Sugie,Nagahiro Minato,Masakazu Toi,Craig T. Morita +15 more
TL;DR: A method for preparing highly enriched human Vγ2Vδ2 T cells using the bisphosphonate prodrug, tetrakis‐pivaloyloxymethyl 2‐(thiazole‐2‐ylamino)ethylidene‐1,1‐bisph phosphonate (PTA).
Journal ArticleDOI
Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy.
Takayuki Ueno,Shigehira Saji,Masahiro Sugimoto,Norikazu Masuda,Katsumasa Kuroi,Nobuaki Sato,Hiroyuki Takei,Yutaka Yamamoto,Shinji Ohno,Hiroko Yamashita,Kazufumi Hisamatsu,Kenjiro Aogi,Hiroji Iwata,Shigeru Imoto,Hironobu Sasano,Masakazu Toi +15 more
TL;DR: It is demonstrated that beclin 1 and LC3 immunoreactivity increased in carcinoma cells following exemestane treatment and that the status of pre-treatment stromal beClin 1 is associated with higher carcinoma cell proliferation and poor clinical and pathological responses to NAE.